Spectral Diagnostics (OTCMKTS:EDTXF – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01), Zacks reports.
Spectral Diagnostics Stock Performance
EDTXF traded down $0.02 on Friday, hitting $0.68. 3,000 shares of the company were exchanged, compared to its average volume of 10,188. The stock’s fifty day moving average is $0.82 and its 200-day moving average is $0.94. Spectral Diagnostics has a 12 month low of $0.64 and a 12 month high of $1.10. The company has a market cap of $201.15 million, a PE ratio of -6.83 and a beta of 0.21.
About Spectral Diagnostics
Spectral Diagnostics Inc is a Canadian medical technology company focused on improving the diagnosis and treatment of sepsis and septic shock. The company develops products designed to identify endotoxin activity, an important factor in certain severe infections and inflammatory conditions.
Its principal diagnostic product is the Endotoxin Activity Assay, a blood test intended to measure a patient’s level of endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis.
Further Reading
- Five stocks we like better than Spectral Diagnostics
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
